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Review
MATERIALS and METHODS
As part of the Vestibular Schwannoma Project conducted by the European Academy of Otology & Neuro-Otology (EAONO), a com-
prehensive literature search was conducted to examine the definition of tumor growth for vestibular schwannoma (VS).
The literature review was conducted on the databases Pubmed and Embase dated back to 20 years (1995-2015) and was updated 
until February 2015.
A PubMed search using the key words “Natural history,” “vestibular schwannoma,” “acoustic neuroma,” and “tumor growth” alone and 
in combination was performed: This query identified 680 papers in the last 20 years, between 1995 and 2015.
Search syntax
 
Inclusion and exclusion criteria
a) Article titles and abstracts were screened according to the following criteria:
b) Clinical articles reporting original data, thereby excluding reviews and case reports
c) Data only from adult patients
EAONO position statement on Vestibular Schwannoma: 
Imaging Assessment Question: How should growth of 
Vestibular Schwannoma be defined?
The relevance of defining the growth of vestibular schwannoma (VS) is that any significant VS growth may impact treatment strategy. A conser-
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d) Series using conservative management; microsurgery, radiosur-
gery, or fractioned stereotactic radiotherapy; and single and/or 
combined treatment for solitary VS
e) More than 50 patients included
f) Quantitative assessment of VS growth as one of the primary 
study end-points
g) Mean follow-up of at least 3 years
h) Studies in which the reported data included patients with neu-
rofibromatosis type 2; if these data could not be separately iden-
tified from the reported data for patients with VS, the articles 
were excluded.
After the initial search, 763 articles were obtained, but 721 did not 
meet one or more of the inclusion criteria and hence were discard-
ed. The remaining 41 articles were reviewed for methodology and 
scored using the Grading of Recommendations Assessment, Devel-
opment and Evaluation (GRADE) system [1].
RESULTS
The question: How should growth of VS be defined?
INTRODUCTION
The relevance of defining the growth of VS is that any significant VS 
growth may impact the treatment strategy. A conservative treatment 
strategy is often proposed as a primary treatment option in the man-
agement of VS. Several authors have demonstrated that a significant 
proportion of VS do not grow, and those that do, usually grow slowly. 
Surgical and/or radiosurgical treatment options may be offered to 
the patient according to VS growth. Therefore, the definition of VS 
growth is a determinant in managing treatment strategies. 
Evidence
The reviewed articles selected to find an answer how should VS growth be 
defined comprised 2 meta-analysis, 6 cohort studies, and 33 case series. The 
mean number of patients included for the clinical series was 215 (50-2500).
Literature review  
      VS GROWTH 
     VS GROWTH CHANGING GRADE GRADE 
  STUDY   RATE STRATEGY Quality of Strength of 
AUTHOR YEAR DESIGN n METHOD mm/year mm/year evidence recommendation
Jethanamest et al. [2] 2015 Case series 94 2 1 1.14 Low Weak
Hougaard et al. [3] 2014 Case series 72 2 1-2 3 Moderate Weak 1
Jeltema et al. [4] 2014 Case series 55 4   Very low Weak
Tang et al. [5] 2014 Case series 88 2,3,4 91.4 mm for   Low Weak 
     1D, 7 mm2 for  
     2D, and 133.3 mm 
     3 for 3D
Niu et al. [6] 2014 Case series 58 4 20%  Low Weak
Nikopoulos et al. [7] 2013 Meta-analysis   1-2 2-4 Moderate Weak
González-Orús  2013 Case series 73 2 2 2 Low Weak 
Álvarez-Morujo et al. [8] 
Stangerup and   2012 Case series prospective 2500 1 3 3 Moderate Weak 2 
Caye-Thomasen [9]
Varughese et al. [10] 2012 Case series prospective 178  4 1 5.22 years VDT Low Weak
Moffat et al. [11] 2012 Case series 381 2  2  Low Weak
Kim et al. [12] 2012 Case series 60 4 20%  Low Weak
Breivik et al. [13] 2012 Case series 193 1 >2 >2 Moderate Weak
Sughrue et al. [14] 2011 Case series prospective 59 2 2.5 2.5 Low Weak 3
Eljamel et al. [15] 2011 Case series 53 1,3 2  Very Low Weak
Varughese et al. [16] 2010 Case series 139 3   Low Weak
Agrawal et al. [17] 2010 Case series 180 1,4 1  Moderate Weak
Suryanarayanan et al. [18] 2010 Case series 286  1.1 (range 0 to 15/y)  Low Weak
Whitehouse, et al. [19] 2010 Case series 88 2 1.24 (range -4,7  Low Weak 
      to 14 mm/y)
Bakkouri et al. [20] 2009 Case series 325 1 1-2 3 Low Weak
Artz et al. [21] 2009 Case series 234 2   Low Weak
Van de Landergerg  2008 Case series 68 4 19.7 %  Moderate Weak 
et al. [22] remark 5        volume change
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The mean VS growth was calculated according to the maximal diam-
eter in the CPA, maximal total diameter, mean of 2 measurements 
and volume changes in 7, 14, 7, and 8 studies, respectively. Once the 
VS reaches 2 cm in intracranial diameter, it is likely to continue grow-
ing. 
The mean VS growth was 1.75±0.83 mm/year but ranged from −13–
+18 mm/year. In 3 studies reporting volume change measurements, 
20% of volume change was considered to be significant growth. A 
minimum of 2 mm/year of VS growth was considered to be signif-
icant for changing management strategies. When considering VS 
Literature review (Continued)
      VS GROWTH 
     VS GROWTH CHANGING GRADE GRADE 
  STUDY   RATE STRATEGY Quality of Strength of 
AUTHOR YEAR DESIGN n METHOD mm/year mm/year evidence recommendation
Ferri et al. [23] 2008 Cohort study 123 2 1.2  Low Weak
Stangerup et al. [24] 2006 Case series prospective 552 2 2 2 Moderate Weak 
Battaglia et al. [25] 2006 Case series 111 3 0.7±1.4  Low Weak
Yoshimoto [26] 2005 Meta-analysis 1340  1.2  Moderate Weak
Flint, et al. [27] 2005 Case series 100  2.7  Low Weak
Hearwadjer et al. [28] 2005 Case series  50 4 109 mm3/y  Low Weak
Bozorg Grayeli et al. [29] 2005 Case series 111 2 1.1±0.21  Low Weak
Raut et al. [30] 2004 Case series prospective 72 3 remark 4 1 3.1 Low Weak
Quaranta et al. [31] 2003 Case series 122  1.09 (range -6.32   Low Weak 
     to 10 mm/y)
Tanaka et al. [32] remark 6 2002 Case series 52 1    Very low Weak
Nutik et al. [33] 2001 Case series 75 1 3.1±2.8  Low Weak
Hoistad et al. [34] 2001 Case series 102 2 2.17  Low Weak
Rosenberg [35] 2000 Case series  80 3  0.91  Low Weak
Mirz et al. [36] 2000 Cohort study 64  2;3  Low Weak
Walsh et al. [37] 2000 Case series 72 3 1.16 (range -  Low Weak 
     0.75 to 9.65/y)
Shin et al.  [38] 2000 Case series 87 3 1.52 (range -  Low Weak 
     13 to 18 mm/y)
Tschudi et al. [39] 2000 Case series 74  2.2 mean first   Low Weak 
     year 2.7
Fucci et al. [40] 1999 Case series 119 2 1.2±3.1  Low Weak
Deen et al. [41] 1996 Case series 68 3 0.72 3 Low Weak
Wiet et al. [42] 1995 Case series 53 2 4.2  Very Low Weak
1 Extrameatal diameter
2 Largest tumor diameter including intracanalicular portio
3 Two-dimensional data,i.e., larger diameter according to AAO-HNS guidelines 1995
4 Volumetric measurements using three-dimensional reconstruction
VS: vestibular schwannoma; VDT volume doubling time; AAO-HNS American Academy of Otolaryngology-Head and Neck Surgery
• *Volume measurements estimated by the slice area method. Tumor areas were measured in each slice of gadolinium-enhanced magnetic resonance imaging (MRI) scans through-
out the entire tumor. Each slide volume was estimated by multiplying the slice area by the slice interval, and the tumor volume was calculated by summarizing all slices. 
• $Volume measurement: (A × B × C)/2 A: anteroposterior diameter; B: medial-to-lateral diameter; C: vertical diameter. Growth in the first year was a strong predictor of future 
growth and a VS volume >1.2 cm3 at presentation was also a predictor of future growth. 
• Remark 1: The best way to measure VS needs further investigation; measurements ought to be standardized and clearly defined, and the current growth criterion ≥1-2 mm needs 
to be redefined. We suggest that VS growth should instead be defined as a 3-mm linear increase in d1 on two consecutive MRI scans one year apart.
• Remark 2: The present criterion for growth of a purely intrameatal tumor was the growth to an extrameatal extension tumor.
• Remark 3: 2.5 mm/year is a clear indication for treatment of patients who wish to maintain hearing.
• Remark 4: The A-P measurement was calculated parallel to the posterior surface of the petrous bone and the M-L measurement was calculated perpendicular to it. The size of the 
tumor was calculated as the square root of the product of these two diameters according to the 1995 guidelines of the AAO-HNS.
• Remark 5: Contrast-enhanced T1-weighted volume measurements showed better interobserver agreement and reliability compared to the two-dimensional measurements for 
the assessment of VS growth. Small intracanalicular VS form an exception. When evaluating VS growth, the VS baseline characteristics should be considered, because standard de-
viation (%) strongly depends on VS size. The 1- or 2-mm difference commonly used to define the growth of VS in consecutive scans in two-dimensional measurements lies within 
the measurement error and should not direct clinical practice.
• Remark 6: The maximum diameter of the CPA portion is the simplest method, and it is appropriate to represent the tumor volume in unselected tumors. The maximum diameter 
or axis diameter with the internal auditory canal portion are better when only small tumors (<0.5 cm3), i.e., tumors with the maximum CPA≤1 cm. 
• Remark 7: Measurements performed on the post-contrast axial T1 images included maximum axial diameter, maximum axial area, total tumor volume, and enhancement pattern. 
An excellent correlation was found between the planar and volumetric methods.
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growth that changed management strategies, values retained were 
3 mm, 2.5, and 2 mm of VS growth per year in 4, 1, and 2 articles, 
respectively.
Although there is an overall low quality of the present studies, all 
highlight a significant VS growth >2 mm, and/or, 1.2 cm3, and/or 20% 
change in volume, and/or the square of the product of the 2 orthog-
onal diameters.
Following the GRADE system, 29 articles were considered to have a 
“low” level of evidence for being observational studies. Furthermore, 
4 observational studies were down-graded to “very low” evidence for 
possible confounding factors. Finally, the 2 meta-analysis and 6 good 
quality observational studies were graded as “moderate” evidence.
CONCLUSION
VS growth should be measured on contrast-enhanced T1 weighted 
images.
Although there is an overall low quality of the present studies, all 
highlight a significant VS growth >2 mm, and/or 1.2 cm3, and/or 20% 
change in volume, and/or the square of the product of the 2 orthog-
onal diameters. We suggest that VS growth should instead change 
management strategies when there is a 3-mm increase in the diame-
ter on two consecutive MRI scans 1 year apart.
Remarks
Most of the available evidence for VS growth comes from retrospec-
tive case series. The follow-up period in these series is quite hetero-
geneous. The VS growth rate should be assessed by VS growth per 
year in further prospective designed studies.
Position EAONO
• There is no high-quality evidence of the definition of VS growth. 
Future studies should try to overcome the present limitations in 
the study design to provide VS growth rate per year.
• Nevertheless, the consistency of results across different studies 
allows for a “moderate” recommendation to consider a signif-
icant VS growth of >2 mm, and/or 1.2 cm3, 20% volume, with 
VS growth rate >3 mm/year as a sign of evolution requiring a 
change in the treatment strategy. 
• The optimal method of measuring VS volumes continues to be 
debated. 
• In literature, the most common method used clinically is to mea-
sure the maximum diameter of the tumor, sometimes excluding 
the dimensions of the intracanalicular component but often in-
cluding the intracanalicular component. 
• The mean growth rate for all tumors, when growing, varies be-
tween 1 and 2 mm/year (1.75±0.83 mm/year) and between 2 
and 4 mm/year for only those that grow. 
• There are various patterns of growth, and a tumor that grows 
may stop growing and vice versa. Nevertheless, the first years of 
observation may give a good estimate of the pattern of growth. 
Some cases can exhibit significant regression or exceptional 
growth. 
• Clinicians should seek to instigate national tumor registries in 
their countries and a common data set to facilitate international 
cooperation. 
• The 2-mm cut-off should be recommended to avoid the effect of 
MRI slice thickness and partial volume effects. Tumor shrinkage 
was defined as tumor-size reduction in any plane by at least 2 mm.
• VS growth rate >3 mm/year should be considered a sign of evo-
lution requiring a change in the treatment strategy.
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Editor’s Note:
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Franco Trabalzini and the Working Groups began working in 2011. Since then a 
considerable work has been issued to produce the first Consensus Documents.
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